<table>
<thead>
<tr>
<th>報告人姓名</th>
<th>關係</th>
<th>類型</th>
<th>金額</th>
<th>SEC 文件</th>
</tr>
</thead>
<tbody>
<tr>
<td>Lee Tien-Li</td>
<td>首席執行官，10% 股東</td>
<td>購買</td>
<td>$101,395</td>
<td>Form 4</td>
</tr>
<tr>
<td>Sun Nelson</td>
<td>首席財務官，10% 股東</td>
<td>購買</td>
<td>$43,200</td>
<td>Form 4</td>
</tr>
</tbody>
</table>
<p>Lee Tien-Li，Aardvark Therapeutics 的首席執行官和 10% 股東，通過以每股 $14.485 的價格購買 7,000 股，擴大了他在公司的股份，總交易金額為 $101,395。此次收購後，Lee Tien-Li 在公司的直接持股總數達到 1,551,613 股，此外還通過配偶間接持有 1,474,028 股。</p>
<p>Sun Nelson，Aardvark Therapeutics 的首席財務官和 10% 股東，也通過以每股 $14.4 的價格購買 3,000 股，增加了他在公司的投資，總金額為 $43,200。這筆交易使 Nelson 的直接持股總數達到 108,484 股。</p>

AARD

<p>Aardvark Therapeutics 的首席執行官李天立和首席財務官孫尼爾森增加了他們在公司的持股。李天立以 101,395 美元購買了 7,000 股，使他的直接持股增至 1,551,613 股，間接持股增至 1,474,028 股。孫尼爾森以 43,200 美元收購了 3,000 股，使他的直接持股增至 108,484 股</p>

<table>
<thead>
<tr>
<th>Reporter Name</th>
<th>Relationship</th>
<th>Type</th>
<th>Amount</th>
<th>SEC Filing</th>
</tr>
</thead>
<tbody>
<tr>
<td>Lee Tien-Li</td>
<td>Chief Executive Officer, 10% Owner</td>
<td>Purchase</td>
<td>$101,395</td>
<td>Form 4</td>
</tr>
<tr>
<td>Sun Nelson</td>
<td>Chief Financial Officer, 10% Owner</td>
<td>Purchase</td>
<td>$43,200</td>
<td>Form 4</td>
</tr>
</tbody>
</table>
<div class="lb-trans"><table>
<thead>
<tr>
<th>報告人姓名</th>
<th>關係</th>
<th>類型</th>
<th>金額</th>
<th>SEC 文件</th>
</tr>
</thead>
<tbody>
<tr>
<td>Lee Tien-Li</td>
<td>首席執行官，10% 股東</td>
<td>購買</td>
<td>$101,395</td>
<td>Form 4</td>
</tr>
<tr>
<td>Sun Nelson</td>
<td>首席財務官，10% 股東</td>
<td>購買</td>
<td>$43,200</td>
<td>Form 4</td>
</tr>
</tbody>
</table>
</div><p>Lee Tien-Li, Chief Executive Officer and 10% Owner of Aardvark Therapeutics, has expanded his stake in the company by purchasing 7,000 shares at a price of $14.485 each, resulting in a total transaction value of $101,395. Following this acquisition, Lee Tien-Li's direct ownership in the company amounts to 1,551,613 shares, with an additional 1,474,028 shares held indirectly through a spouse.</p>
<div class="lb-trans"><p>Lee Tien-Li，Aardvark Therapeutics 的首席執行官和 10% 股東，通過以每股 $14.485 的價格購買 7,000 股，擴大了他在公司的股份，總交易金額為 $101,395。此次收購後，Lee Tien-Li 在公司的直接持股總數達到 1,551,613 股，此外還通過配偶間接持有 1,474,028 股。</p>
</div><p>Sun Nelson, Chief Financial Officer and 10% owner of Aardvark Therapeutics, also increased his investment in the company by acquiring 3,000 shares at a price of $14.4 per share, totaling $43,200. This transaction brings Nelson's direct ownership to 108,484 shares.</p>
<div class="lb-trans"><p>Sun Nelson，Aardvark Therapeutics 的首席財務官和 10% 股東，也通過以每股 $14.4 的價格購買 3,000 股，增加了他在公司的投資，總金額為 $43,200。這筆交易使 Nelson 的直接持股總數達到 108,484 股。</p>
</div>

Aardvark Therapeutics 的高管們增加了他們的持股量